Oestrogen-related tumour phenotype: positron emission tomography characterisation with18F-FDG and18F-FES

This article outlines the role of 16α-[18F]fluoro-17β-oestradiol (18F-FES) positron emission tomography (PET) combined with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) in patients with oestrogen-related tumours for evaluating tumour phenotype. 18F-FES-PET combined with 18F-FDG is helpful in characterising the distinct phenotypic features of oestrogen-related tumours; that is, inter- and intrapatient tumour heterogeneity, which indicates its great potential as a determinant of individualised treatment and a prognostic predictor for patients with oestrogen-related tumours.